Solution designed to maintain sinus rhythm in patients with Atrial Fibrillation

Maxwell Biomedical is pioneering advancements in cardiac care with its innovative Spatial Resynchronization Therapy (SRT) System, specifically designed for patients suffering from both atrial fibrillation (AF) and heart failure. This non-ablative therapy utilizes ultra-low energy stimulation to effectively restore and maintain Functional Sinus Rhythm (SR) without the discomfort and risks associated with traditional high-energy cardioversion. The SRT System not only aims to terminate AF episodes but also enhances left atrial function, which is crucial for improving cardiac output in heart failure patients. Early trials have shown promising results, with a high success rate in restoring normal rhythm, indicating the potential of this technology to significantly improve patient outcomes.

In addition to its therapeutic capabilities, the SRT System incorporates advanced monitoring features that allow for continuous tracking of various cardiac parameters, including premature atrial contractions and left atrial pressure. This real-time data collection enables the system to detect early warning signs of AF and implement preemptive strategies to prevent episodes. By integrating tele-health management, Maxwell Biomedical's device supports comprehensive patient care, facilitating remote monitoring and timely interventions. This holistic approach not only addresses the immediate challenges of AF and heart failure but also promotes long-term health improvements for patients.

United States

Maxwell Biomedical is Pioneering a Non-Ablative AF Solutions for Lifelong Functional Sinus Rhythm and Heart Failure Management 
– Seamless Treatment, Proactive Care

Maxwell Biomedical

Company Details